

# Carcinoma of the Stomach Histopathology Reporting Guide



Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

Elements in **black text** are **CORE**. Elements in **grey text** are **NON-CORE**.

[SCOPE OF THIS DATASET](#)

indicates multi-select values     indicates single select values

**CLINICAL INFORMATION** (select all that apply)

- Information not provided
- Relevant biopsy results, *specify*
- Previous diagnosis and treatment for gastric cancer, *specify*
- Endoscopic location of the tumour, *specify*
- Clinical staging, *specify level of involvement, distant metastases*
- Previous partial gastrectomy procedure, *specify*
- History of chronic gastritis, *specify*
- Other, *specify*

**NEOADJUVANT THERAPY**

- Information not provided
- Not administered
- Administered, *describe*

**OPERATIVE PROCEDURE**

- Not specified
- Gastrectomy
  - Sub-total
  - Total
- Oesophagogastrectomy
- Other, *specify*

**SPECIMEN DIMENSIONS**

Length of stomach greater curve	<input style="width: 100%; height: 25px;" type="text" value="mm"/>
Length of stomach lesser curve	<input style="width: 100%; height: 25px;" type="text" value="mm"/>
Length of oesophagus	<input style="width: 100%; height: 25px;" type="text" value="mm"/>
Length of duodenum	<input style="width: 100%; height: 25px;" type="text" value="mm"/>

**TUMOUR FOCALITY<sup>a</sup>**

- Unifocal
- Multifocal, *specify number of tumours in specimen*
- Cannot be assessed, *specify*

<sup>a</sup> If multiple primary tumours are present, separate datasets should be used to record this and all following elements for each primary tumour.

**TUMOUR SITE** (select all that apply) 

- Not specified
- Region  
 Upper third     Middle third     Distal third
- Curvature  
 Greater     Lesser
- Wall  
 Anterior     Posterior
- Other, *specify*

**TUMOUR DIMENSIONS** 

Maximum tumour dimension

 mm

Additional dimensions

 mm x  mm

- Cannot be assessed, *specify*

**MACROSCOPIC TUMOUR TYPE** 

- Not applicable
- Cannot be assessed
- Polypoid mass (Borrmann type I)
- Ulcerative (Borrmann type II)
- Infiltrative ulcerative (Borrmann type III)
- Diffuse infiltrative (Borrmann type IV)
- Other, *specify*

**HISTOLOGICAL TUMOUR TYPE** **World Health Organization (WHO) Classification**

(Value list based on the WHO Classification of Tumours of the Gastrointestinal Tract (2019))

- Cannot be assessed
- Tubular adenocarcinoma
- Papillary adenocarcinoma
- Mucinous adenocarcinoma
- Poorly cohesive carcinoma, including signet-ring cell carcinoma and other subtypes
- Mixed adenocarcinoma
- Other histological type/subtype, *specify*

**Laurén Classification**

(Applicable to gastric adenocarcinomas)

- Intestinal
- Diffuse
- Mixed
- Indeterminate

**HISTOLOGICAL TUMOUR GRADE** 

- Not applicable
- Cannot be assessed
- Low grade (well and moderately differentiated)
- High grade (poorly differentiated)
- Other, *specify*

**EXTENT OF INVASION** 

- Cannot be assessed
- No evidence of primary tumour
- Carcinoma in situ (intraepithelial tumour without invasion of the lamina propria, high grade dysplasia)
- Invasion into the lamina propria
- Invasion into the muscularis mucosae
- Invasion into the submucosa
- Invasion into the muscularis propria
- Invasion into the subserosal connective tissue (without invasion of the visceral peritoneum or adjacent structures)
- Invasion into the serosa (visceral peritoneum)
- Invasion into adjacent structure(s)/organ(s), *specify*

**LYMPHOVASCULAR INVASION** 

- Not identified
- Present

**PERINEURAL INVASION** 

- Not identified
- Present

**RESPONSE TO NEOADJUVANT THERAPY** 

- No neoadjuvant treatment
- Complete response - no viable cancer cells (score 0)
- Near complete response - single cells or rare small groups of cancer cells (score 1)
- Partial response - residual cancer with evident tumour regression, but more than single cells or rare groups of cancer cells (score 2)
- Poor or no response - extensive residual cancer with no evident tumour regression (score 3)
- Cannot be assessed, *specify*

**MARGIN STATUS** 

**Invasive carcinoma**

- Cannot be assessed
- Not involved
  - Distance of tumour from closest margin  mm
  - Specify closest margin, if possible
- Involved (select all that apply)
  - Distal
  - Proximal
  - Circumferential/Radial

**Dysplasia**

- Cannot be assessed
- Not involved
- Involved
  - Carcinoma in situ/high grade dysplasia
  - Low grade
- Specify margin (select all that apply)
  - Distal
  - Proximal
  - Other, *specify*

**LYMPH NODE STATUS** (Note 16) 

- Cannot be assessed
- No nodes submitted or found
- Number of lymph nodes examined
- Not involved
- Involved
  - Number of involved lymph nodes

**COEXISTENT PATHOLOGY** (select all that apply) 

- None identified
- Helicobacter* gastritis
- Autoimmune gastritis
- Reactive gastritis
- Intestinal metaplasia
- Gastric polyps, *specify*
- Dysplasia
  - Low grade
  - High grade
  - Indeterminate
- Synchronous carcinoma(s), *specify*
- Other, *specify*

**ANCILLARY STUDIES** 

**For neuroendocrine neoplasms only**

- Not applicable
- Neuroendocrine markers (chromogranin A, synaptophysin, other), *specify test(s) performed and result(s) if available*

AND  
Ki-67 proliferation index  %

**Other gastric carcinomas**

- Not performed
- Performed (select all that apply)
  - HER2 testing performed, *record result(s)*
  - Microsatellite instability (MSI)/Mismatch repair (MMR) testing, *record result(s)*
  - Epstein-Barr virus (EBV)-status (e.g., EBV encoded RNA (EBER) in situ hybridisation), *record result(s)*
  - Other, *specify test(s) and result(s)*

**HISTOLOGICALLY CONFIRMED DISTANT METASTASES** 

- Not identified
- Present, *specify site(s)*

**PATHOLOGICAL STAGING (UICC TNM 8<sup>th</sup> edition)<sup>b</sup>** **TNM Descriptors** (only if applicable) (select all that apply)

- m - multiple primary tumours  
 r - recurrent  
 y - post-therapy

**Primary tumour (pT)**

- TX Primary tumour cannot be assessed  
 T0 No evidence of primary tumour  
 Tis Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria, high grade dysplasia  
 T1 Tumour invades lamina propria, muscularis mucosae, or submucosa  
 T1a Tumour invades lamina propria or muscularis mucosae  
 T1b Tumour invades submucosa  
 T2 Tumour invades muscularis propria  
 T3 Tumour invades subserosa  
 T4 Tumour perforates serosa (visceral peritoneum) or invades adjacent structures<sup>c,d,e</sup>  
 T4a Tumour perforates serosa  
 T4b Tumour invades adjacent structures<sup>c,d</sup>

**Regional lymph nodes (pN)**

- NX Regional lymph node(s) cannot be assessed  
 N0 No regional lymph node metastasis  
 N1 Metastasis in 1 to 2 regional lymph nodes  
 N2 Metastasis in 3 to 6 regional lymph nodes  
 N3 Metastasis in 7 or more regional lymph nodes  
 N3a Metastasis in 7 to 15 regional lymph nodes  
 N3b Metastasis in 16 or more regional lymph nodes

<sup>b</sup> Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8<sup>th</sup> Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley.

<sup>c</sup> The adjacent structures of the stomach are the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.

<sup>d</sup> Intramural extension to the duodenum or oesophagus is classified by the depth of greatest invasion in any of these sites including stomach.

<sup>e</sup> Tumour that extends into gastrocolic or gastrohepatic ligaments or into greater or lesser omentum, without perforation of visceral peritoneum, is T3.